Background: Ozempic is a GLP-1 receptor agonist indicated for the treatment of T2DM. However, its effectiveness in suppressing appetite and reducing weight has led to increased off-label use by non-diabetic individuals, especially for aesthetic purposes. These changing patterns of use have raised concerns about long-term side effects, misuse, and a crisis of access to medication for diabetes patients who need it. Purpose: This article examines the transformation of Ozempic from a metabolic therapy drug to an aesthetic accessory, driven by the virality of social media content. This phenomenon not only triggers therapeutic exclusion for diabetic patients, but also opens ethical discussions about drug distribution, pharmaceutical commercialization, and the risks of using outside medical indications. Method: This study conducted a literature review of recent articles, reports, and relevant publications related to the adverse effects and distribution disparities of Ozempic. Results: Data shows a 594% increase in global use of GLP-1RAs between 2020 and 2023, with a 659% increase in women aged 18 - 25 and a 481% increase in men. Ozempic sales are expected to surge 26% in 2024 to $40.5 billion for Novo Nordisk, and 32% to $45 billion for Eli Lilly. This surge coincides with reports of Ozempic shortages, which have a direct impact on high-risk T2DM patients. Conclusion: The use of Ozempic outside of medical indications shows the need for strict regulation, balanced public education, and equitable distribution of drugs. Without intervention, this trend could worsen therapeutic exclusion and shift the function of essential drugs into aesthetic commodities.
References
[1]
Wang, J., Wang, Q., Yang, X., Yang, W., Li, D., Jin, J., et al. (2023) GLP-1 Receptor Agonists for the Treatment of Obesity: Role as a Promising Approach. FrontiersinEndocrinology, 14, Article 1085799. https://doi.org/10.3389/fendo.2023.1085799
[2]
Drucker, D.J. (2018) Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. CellMetabolism, 27, 740-756. https://doi.org/10.1016/j.cmet.2018.03.001
[3]
Hinnen, D. (2017) Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. DiabetesSpectrum, 30, 202-210. https://doi.org/10.2337/ds16-0026
[4]
Røder, M.E. (2019) Clinical Potential of Treatment with Semaglutide in Type 2 Diabetes Patients. DrugsinContext, 8, 1-11. https://doi.org/10.7573/dic.212585
[5]
Dhillon, S. (2018) Semaglutide: First Global Approval. Drugs, 78, 275-284. https://doi.org/10.1007/s40265-018-0871-0
[6]
Mailhac, A., Pedersen, L., Pottegård, A., Søndergaard, J., Mogensen, T., Sørensen, H., et al. (2024) Semaglutide (Ozempic®) Use in Denmark 2018 through 2023—User Trends and Off-Label Prescribing for Weight Loss. ClinicalEpidemiology, 16, 307-318. https://doi.org/10.2147/clep.s456170
[7]
Singh, G., Krauthamer, M. and Bjalme-Evans, M. (2022) Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management. JournalofInvestigativeMedicine, 70, 5-13. https://doi.org/10.1136/jim-2021-001952
[8]
Raubenheimer, J.E., Myburgh, P.H. and Bhagavathula, A.S. (2024) Sweetening the Deal: An Infodemiological Study of Worldwide Interest in Semaglutide Using Google Trends Extended for Health Application Programming Interface. BMCGlobalandPublicHealth, 2, Article No. 63. https://doi.org/10.1186/s44263-024-00095-w
[9]
Scannell, C., Romley, J., Myerson, R., Goldman, D. and Qato, D.M. (2024) Prescription Fills for Semaglutide Products by Payment Method. JAMAHealthForum, 5, e242026. https://doi.org/10.1001/jamahealthforum.2024.2026
[10]
Grogan, S. (2016) Body Image: Understanding Body Dissatisfaction in Men, Women and Children. 3rd Edition, Routledge, 1-214.
[11]
World Health Organization (2016) Overweight and Obesity: Adults Ages 18+. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
[12]
Wati, D.K. and Sumarmi, S. (2017) Citra Tubuh Pada Remaja Perempuan Gemuk Dan Tidak Gemuk: Studi Cross Sectional. AmertaNutrition, 1, 398-405. https://doi.org/10.20473/amnt.v1i4.7130
[13]
Callaghan, T., Motta, M., Stein, M. and Goidel, K. (2025) The Prevalence and Consequences of Support for Off-Label Ozempic Prescriptions. HealthEconomics, PolicyandLaw, 20, 330-343. https://doi.org/10.1017/s1744133124000306
[14]
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., et al. (2020) Pathophysiology of Type 2 Diabetes Mellitus. InternationalJournalofMolecularSciences, 21, Article 6275. https://doi.org/10.3390/ijms21176275
[15]
Zhou, B., Lu, Y., Hajifathalian, K., Bentham, J., Di Cesare, M., Danaei, G., et al. (2016) Worldwide Trends in Diabetes since 1980: A Pooled Analysis of 751 Population-Based Studies with 4·4 Million Participants. TheLancet, 387, 1513-1530. https://doi.org/10.1016/s0140-6736(16)00618-8
[16]
International Diabetes Federation (2025) IDF Diabetes Atlas 11th Edition.
[17]
The Lancet Diabetes & Endocrinology, (2024) Alarming Rise in Young-Onset Type 2 Diabetes. TheLancetDiabetes&Endocrinology, 12, 433. https://doi.org/10.1016/s2213-8587(24)00161-x
[18]
Nachawi, N., Rao, P.P. and Makin, V. (2022) The Role of GLP-1 Receptor Agonists in Managing Type 2 Diabetes. ClevelandClinicJournalofMedicine, 89, 457-464. https://doi.org/10.3949/ccjm.89a.21110
[19]
Shandilya, A. and Mehan, S. (2021) Dysregulation of IGF-1/GLP-1 Signaling in the Progression of ALS: Potential Target Activators and Influences on Neurological Dysfunctions. NeurologicalSciences, 42, 3145-3166. https://doi.org/10.1007/s10072-021-05328-6
[20]
Hamed, K., Alosaimi, M.N., Ali, B.A., Alghamdi, A., Alkhashi, T., Alkhaldi, S.S., et al. (2024) Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health through a Comprehensive Literature Review. Cureus, 16, e68390. https://doi.org/10.7759/cureus.68390
[21]
Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jódar, E., Leiter, L.A., et al. (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NewEnglandJournalofMedicine, 375, 1834-1844. https://doi.org/10.1056/nejmoa1607141
[22]
Koman, A.M., Przygodzka, S., Gadżała, K., Janik, I., Pliszka, M., Palacz, K.A., et al. (2024) Ozempic (Semaglutide)—Review of Pharmacological Properties, Mechanism of Action and Clinical Applications. QualityinSport, 16, 52659. https://doi.org/10.12775/qs.2024.16.52659
[23]
Feier, C., Vonica, R., Faur, A., Streinu, D. and Muntean, C. (2024) Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. InternationalJournalofMolecularSciences, 25, Article 4346. https://doi.org/10.3390/ijms25084346
[24]
Roy, T. (2024) Young People Are Increasingly Using Wegovy and Ozempic. Michigan Medicine. https://www.michiganmedicine.org/health-lab/young-people-are-increasingly-using-wegovy-and-ozempic
[25]
Muñoz, E., Grant, K., Thelus, R. and Secora, A. (2024) EPH202 Assessing Trends in Utilization and Off-Label Prescribing for Ozempic, a Glucagon-Like Peptide Receptor Agonist. ValueinHealth, 27, S188. https://doi.org/10.1016/j.jval.2024.03.2316
[26]
Shadbolt, C., Elkin, J., Schilling, C., Hua, X., Choong, P.F.M. and Dowsey, M.M. (2025) National Trends in Glucagon-Like Peptide-1 Receptor Agonist Use in Adults without Diabetes, 2018 to 2022. AnnalsofInternalMedicine, 178, 896-898. https://doi.org/10.7326/annals-24-02878
Tan, H.C., Dampil, O.A. and Marquez, M.M. (2022) Efficacy and Safety of Semaglutide for Weight Loss in Obesity without Diabetes: A Systematic Review and Meta-Analysis. Journal of the ASEAN Federation of Endocrine Societies, 37, 65-72. https://doi.org/10.15605/jafes.037.02.14
[29]
Pazzagli, L. and Trolle Lagerros, Y. (2024) Socioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study. Obesity Facts, 18, 130-138. https://doi.org/10.1159/000542682
[30]
Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D.M., et al. (2021) Managing the Gastrointestinal Side Effects of GLP-1 Receptor Agonists in Obesity: Recommendations for Clinical Practice. Postgraduate Medicine, 134, 14-19. https://doi.org/10.1080/00325481.2021.2002616
[31]
Bharucha, A.E., Camilleri, M., Veil, E., Burton, D. and Zinsmeister, A.R. (2012) Comprehensive Assessment of Gastric Emptying with a Stable Isotope Breath Test. Neurogastroenterology & Motility, 25, e60-e69. https://doi.org/10.1111/nmo.12054
[32]
Nauck, M.A. and Meier, J.J. (2018) Incretin Hormones: Their Role in Health and Disease. Diabetes, Obesity and Metabolism, 20, 5-21. https://doi.org/10.1111/dom.13129
[33]
Sodhi, M., Rezaeianzadeh, R., Kezouh, A. and Etminan, M. (2023) Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA, 330, 1795-1797. https://doi.org/10.1001/jama.2023.19574
[34]
Tay, J.Q. (2023) Ozempic Face: A New Challenge for Facial Plastic Surgeons. Journal of Plastic, Reconstructive & Aesthetic Surgery, 81, 97-98. https://doi.org/10.1016/j.bjps.2023.04.057
[35]
Cleveland Clinic (2025) What Is ‘Ozempic Face’ and How to Prevent It. https://health.clevelandclinic.org/ozempic-face
[36]
(2025) What to Know about “Ozempic Face”. https://www.medicalnewstoday.com/articles/ozempic-face
[37]
Rodrigues, L., Palma, L., Tavares Marques, L. and Bujan Varela, J. (2015) Dietary Water Affects Human Skin Hydration and Biomechanics. Clinical, Cosmetic and Investigational Dermatology, 8, 413-421. https://doi.org/10.2147/ccid.s86822
[38]
Al-Atif, H. (2022) Collagen Supplements for Aging and Wrinkles: A Paradigm Shift in the Field of Dermatology and Cosmetics. DermatologyPractical&Conceptual, 12, e2022018. https://doi.org/10.5826/dpc.1201a18
[39]
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F.L., Jensen, C., et al. (2021) Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity. JAMA, 325, 1414-1425. https://doi.org/10.1001/jama.2021.3224
[40]
Tobaiqy, M. and Elkout, H. (2024) Psychiatric Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Pharmacovigilance Analysis of Individual Case Safety Reports Submitted to the Eudravigilance Database. InternationalJournalofClinicalPharmacy, 46, 488-495. https://doi.org/10.1007/s11096-023-01694-7
[41]
(2025) ‘Ozempic Personality’: How Weight Loss Drugs Can Affect Your Behavior. https://www.healthline.com/health-news/ozempic-personality-change
[42]
Zhu, C., Li, H., Kong, X., Wang, Y., Sun, T. and Wang, F. (2022) Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder. FrontiersinPharmacology, 13, Article 819470. https://doi.org/10.3389/fphar.2022.819470
[43]
Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., et al. (2022) Tirzepatide Once Weekly for the Treatment of Obesity. NewEnglandJournalofMedicine, 387, 205-216. https://doi.org/10.1056/nejmoa2206038
[44]
Bonnet, J.P., Cardel, M.I., Cellini, J., Hu, F.B. and Guasch-Ferré, M. (2020) Breakfast Skipping, Body Composition, and Cardiometabolic Risk: A Systematic Review and Meta-Analysis of Randomized Trials. Obesity, 28, 1098-1109. https://doi.org/10.1002/oby.22791
[45]
Admani, B., Fahim, M. and Ahmed, H. (2024) Semaglutide and Weight Loss—A Concern for Diabetics and Pharmaceuticals. JournalofthePakistanMedicalAssociation, 74, 1204-1204. https://doi.org/10.47391/jpma.10705
[46]
Emanuel, E.J., Persad, G., Upshur, R., Thome, B., Parker, M., Glickman, A., et al. (2020) Fair Allocation of Scarce Medical Resources in the Time of Covid-19. NewEnglandJournalofMedicine, 382, 2049-2055. https://doi.org/10.1056/nejmsb2005114
[47]
Rajasekaran, S., Rajaguru, P. and Sudhakar Gandhi, P.S. (2015) MicroRNAs as Potential Targets for Progressive Pulmonary Fibrosis. FrontiersinPharmacology, 6, Article 254. https://doi.org/10.3389/fphar.2015.00254
[48]
AFFA Intellectual Property Rights (2024) Legal Implications of Counterfeit Drugs in Indonesia. AFFA Intellectual Property Rights. https://affa.co.id/global/2024/09/13/legal-implications-of-counterfeit-drugs-in-indonesia/
[49]
Kushner, R.F., Calanna, S., Davies, M., Dicker, D., Garvey, W.T., Goldman, B., et al. (2020) Semaglutide 2.4 Mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity, 28, 1050-1061. https://doi.org/10.1002/oby.22794
[50]
Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., et al. (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. NewEnglandJournalofMedicine, 384, 989-1002. https://doi.org/10.1056/nejmoa2032183
[51]
Garvey, W.T., Mechanick, J.I., Brett, E.M., Garber, A.J., Hurley, D.L., Jastreboff, A.M., et al. (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. EndocrinePractice, 22, 1-203. https://doi.org/10.4158/ep161365.gl
[52]
Basch, C.H., Narayanan, S., Tang, H., Fera, J. and Basch, C.E. (2023) Descriptive Analysis of TikTok Videos Posted under the Hashtag #Ozempic. JournalofMedicine, Surgery, andPublicHealth, 1, Article ID: 100013. https://doi.org/10.1016/j.glmedi.2023.100013
[53]
Badan Pengawas Obat dan Makanan Republik Indonesia (BPOM) (2021) Pedoman Pengawasan Obat dan Makanan di Indonesia.
[54]
World Health Organization (2024) WHO Global Benchmarking Tool (GBT) for Evaluation of National Regulatory System of Medical Products Manual for Benchmarking and Formulation of Institutional Development Plans. https://www.who.int/publications/i/item/9789240087637
